AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Biohit Oyj

Director's Dealing Mar 1, 2017

3304_rns_2017-03-01_a793e0a5-b151-4a62-ae59-32b16ffac5a5.html

Director's Dealing

Open in Viewer

Opens in native device viewer

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions

Biohit Oyj - Managers' Transactions, March 1, 2017 at 11:50 am local time (EET)

Person subject to the notification requirement
Name: Euroclone Spa Legal Person
Position: Closely associated person

Person discharging managerial responsibilities in issuer
Name: Aiolfi, Franco
Position: Member of the Board/Deputy member


Initial Notification
Reference number: 74370089ATTSNBXJVT29_20170227134828_12


Issuer
Name: Biohit Oyj
LEI: 74370089ATTSNBXJVT29


Transaction details
Transaction date: 2017-02-24
Venue: NASDAQ HELSINKI LTD (XHEL)
Nature of the transaction: Exercise (Rights, Put and Call Options)

Instrument: Share
ISIN: FI0009005482

Volume: 475
Unit price: 5,56000 Euro
Volume: 458
Unit price: 5,57000 Euro
Volume: 1000
Unit price: 5,56000 Euro
Volume: 200
Unit price: 5,55000 Euro
Volume: 200
Unit price: 5,56000 Euro
Volume: 100
Unit price: 5,57000 Euro
Volume: 1500
Unit price: 5,57000 Euro
Volume: 200
Unit price: 5,55000 Euro
Volume: 150
Unit price: 5,55000 Euro
Volume: 62
Unit price: 5,55000 Euro
Volume: 200
Unit price: 5,55000 Euro
Volume: 69
Unit price: 5,55000 Euro
Volume: 35
Unit price: 5,55000 Euro
Volume: 50
Unit price: 5,55000 Euro
Volume: 200
Unit price: 5,55000 Euro
Volume: 1000
Unit price: 5,55000 Euro
Volume: 160
Unit price: 5,55000 Euro
Volume: 25
Unit price: 5,55000 Euro

Aggregated transactions
Volume: 6084
Volume weighted average price: 5.55952 Euro

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
[email protected]
www.biohithealthcare.com

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s
mission is “Innovating for Health” – we produce innovative products and
services to promote research and early diagnosis. Biohit is headquartered in
Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B
share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.
www.biohithealthcare.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.